Daunorubicin continuous infusion induces more toxicity than bolus infusion in acute lymphoblastic leukemia induction regimen: a randomized study
暂无分享,去创建一个
M. Bernard | N. Ifrah | F. Guilhot | N. Milpied | M. Hunault-Berger | P Casassus | M Hunault-Berger | N Milpied | M Bernard | J-P Jouet | M Delain | B Desablens | A Sadoun | F Guilhot | N Ifrah | M. Delain | B. Desablens | P. Casassus | A. Sadoun | J. Jouet | Jouet Jp
[1] E. Estey,et al. Acute lymphocytic leukaemia in the elderly: characteristics and outsome with the vincristine‐adriamycin‐dexamethasone (VAD) regimen , 1994, British journal of haematology.
[2] FRCP W. J. MacLennan MD,et al. The Elderly , 1984, Treatment in Clinical Medicine.
[3] G. Heller,et al. Development of a new intensive therapy for acute lymphoblastic leukemia in children at increased risk of early relapse: The memorial Sloan‐Kettering‐New York‐II protocol , 1993, Cancer.
[4] C. Pui,et al. Acute lymphoblastic leukemia. , 1998, The New England journal of medicine.
[5] F. Meyers,et al. Daunomycin administered by continuous intravenous infusion is effective in the treatment of acute nonlymphocytic leukaemia , 1985, British journal of haematology.
[6] A. Veerman,et al. Acute toxicity and effectiveness of idarubicin in childhood acute lymphoblastic leukemia , 1997, European journal of haematology.
[7] D. Hoelzer. Therapy of the newly diagnosed adult with acute lymphoblastic leukemia. , 1993, Hematology/oncology clinics of North America.
[8] M. Zucchetti,et al. Short course infusional idarubicin plus intermittent cytarabine and etoposide for refractory hematologic malignancies: clinical and preliminary pharmacological results. , 1998, Haematologica.
[9] E. Estey,et al. Results of the vincristine, doxorubicin, and dexamethasone regimen in adults with standard- and high-risk acute lymphocytic leukemia. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] E. Henderson,et al. Efficacy of daunorubicin in the therapy of adult acute lymphocytic leukemia: a prospective randomized trial by cancer and leukemia group B. , 1984, Blood.
[11] C. Pegelow,et al. Cellular and plasma kinetics of daunorubicin given by two methods of administration in a patient with acute leukemia. , 1982, Cancer treatment reports.
[12] J. Lau,et al. Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] Peter Shaw,et al. Induction toxicity of a modified Memorial Sloan-Kettering-New York II Protocol in children with relapsed acute lymphoblastic leukemia: a single institution study. , 1996, Medical and pediatric oncology.
[14] V. Pavone,et al. Continuous infusion chemotherapy with epirubicin and vincristine in relapsed and refractory acute leukemia. , 1990, Acta haematologica.
[15] C. Sebban,et al. Continuous-infusion daunorubicin and carboplatin for high-risk acute myeloid leukemia in the elderly. , 1992, Leukemia.
[16] O. Ottmann,et al. Growth factors in the treatment of acute lymphoblastic leukemia. , 1998, Leukemia research.
[17] R. Carlson,et al. Continuous infusion or bolus injection in cancer chemotherapy. , 1983, Annals of internal medicine.
[18] E. Copelan,et al. The biology and treatment of acute lymphoblastic leukemia in adults. , 1995, Blood.
[19] Y. Ozisik,et al. Bolus and continuous infusion mitoxantrone in newly diagnosed adult acute lymphoblastic leukemia: results of two consecutive phase II clinical studies. , 1998, Cancer investigation.
[20] M. Sack,et al. Clinical evaluation of long-term, continuous-infusion doxorubicin. , 1983, Cancer treatment reports.
[21] K. Remes,et al. VAD regimen in the treatment of resistant multiple myeloma: slow or fast infusion? , 1993, Leukemia & lymphoma.
[22] B. D. de Pauw,et al. CELLULAR PHARMACOKINETICS OF DAUNOMYCIN ADMINISTERED AS CONTINUOUS INTRAVENOUS INFUSION IN THE TREATMENT OF ACUTE NON‐LYMPHOCYTIC LEUKAEMIA , 1986, British journal of haematology.